Start exploring your own markets for free

🚀 Try for Free

AI Therapeutics

Light Search completed

Invite

Radar Tracking

Subspaces (4)

Drug Discovery Optimization

Biomarker Identification

Genomic Data Analysis

Drug Repurposing

Pending to review

Not sure yet

Interested

Not interested

Download list

Showing 104 results

Company	Fit assessment	Description	Subspaces	Tags	HQ Location	Founding Date	Employees	Total Funding Raised	Last Funding Event	Received on
Metanovas Biotech	Metanovas effectively leverages machine learning for drug discovery and repurposing, demonstrating a strong commitment to expanding therapeutic options.	Provider of an AI-enabled drug and disease discovery platform. The company provides a drug and disease discovery platform empowered by machine learning and AI to discover novel disease targets, screen for potential drugs, repurpose existing drugs for new indication and optimization ADMET property prediction, enabling a more efficient way to generate new insights and discover more effective medicines to decipher disease biology.	Drug Repurposing	Light Search	United States	2021	11 - 50	$10.00M	Seed, $10.00M, March 31, 2022	Oct 14, 2024
VeriSIM Life	VeriSIM Life effectively leverages machine learning to enhance drug development, discover patterns in drug interactions, and expand therapeutic options, including drug repurposing.	Developer of a disease-specific simulation software designed to replace animal drug testing by using artificial intelligence. The company's software helps to increase human life expectancy through intelligence-driven biosystem simulations to personalize patient treatment and uses advanced computational approaches to allow researchers to design proprietary chemical entities, compounds, and drug candidates more quickly and economically, enabling pharmaceutical scientists to improve the accuracy and efficiency of drug development and make personalized health care a reality.	Drug Repurposing	Light Search	United States	2017	11 - 50	$21.66M	Series A, $15.00M, January 13, 2022	Oct 14, 2024
Pending AI	Pending.AI effectively utilizes machine learning to enhance drug discovery, pattern discovery, and the development of new therapeutics.	Developer of comprehensive discovery platform enabled by artificial intelligence and quantum mechanics, ushering in a new paradigm of medicinal innovation where higher-quality small molecule drugs can be developed in a fraction of the time and cost. The company's operation are presences across both Boston, Massachusetts, United States and Eveleigh, New South Wales, Australia, enabling scientists in the pharmaceutical industry to design, make, and test new drugs to treat diseases.	Drug Discovery Optimization	Light Search	Australia	2018	1 - 10		Venture - Series Unknown, January 1, 2021	Oct 14, 2024
REPO4EU	REPO4EU effectively leverages machine learning for drug repurposing, discovering new patterns in disease mechanisms, and expanding therapeutic options.	REPO4EU is the Euro/Global Platform for Drug Repurposing - from imprecise drug therapy to AI-powered precision medicine. Should you need any help in searching for bioinformatics support for an unmet medical need, a registered compound or a specific mechanism; exploring your freedom to operate or a patenting strategy or regulatory advice; liaising with a business partner, setting up a clinical trial test site for phase I-III or crafting a business plan... we have the experts and global experience to help and work with you!	Drug Repurposing	Light Search	United States	2022	11 - 50		NA	Oct 14, 2024
Cancerappy	Cancerappy effectively utilizes machine learning and AI to enhance cancer research, discover new therapeutic targets, and optimize drug discovery processes.	Developer of a novel artificial intelligence platform designed to optimize cancer drug development and personalized medicine. The company's algorithms are based on molecular alterations, scientific results, clinical trials, combinations of compounds, described efficacy, and competitive landscape, enabling scientists to move faster and better in their research work.	Drug Discovery Optimization	Light Search	Bilbao (Spain)	2019	1 - 10		NA	Oct 14, 2024
Fasttrac	Fasttrac leverages machine learning and advanced computational methods to discover novel molecules, optimizing the drug discovery process and expanding therapeutic options.	Our computational Software as a Service (SaaS), Platform as a Service (PaaS) and Technology as a Service (TaaS) platform is capable of predicting critical properties of molecules with a high degree of accuracy. This critical capability enables drug discovery teams to design and selectively synthesize molecules with more optimal properties, reducing the average time and costs required to identify a development candidate and increasing the probability that a drug discovery program will enter clinical development.	Drug Discovery Optimization	Light Search	United States	2019	1 - 10		NA	Oct 14, 2024
Insitro	Insitro effectively utilizes machine learning to discover patterns and expand therapeutics, optimizing the drug discovery process.	Operator of a data-driven drug discovery and development company intended to transform how drugs are discovered and delivered to patients. The company uses machine learning and high-throughput biology to create massive data sets to be brought to bear on key bottlenecks in pharmaceutical R&D, enabling drug development companies to have predictive models that are used to accelerate target selection, design, and develop effective therapeutics, and to inform clinical strategy.	Drug Repurposing Drug Discovery Optimization	Light Search	South San Francisco (United States)	2018	51 - 200	$643.00M	Series C, $400.00M, March 15, 2021	Oct 14, 2024
Medvolt	Medvolt effectively leverages machine learning to discover patterns and expand therapeutics, including drug repurposing capabilities.	Developer of biomedical research platform designed to accelerate life sciences research. The company focuses on accelerating drug discovery and development by democratizing access to AI-powered technology and clean data by leveraging a highly modular and data-driven, thereby reducing costs and increasing the probability of success.	Drug Repurposing	Light Search	India	2021	1 - 10		NA	Oct 14, 2024
Illumina	Illumina specializes in advanced technologies for analyzing genetic material, focusing on DNA, RNA, and protein analysis to support disease research and drug development. Their solutions aim to facilitate personalized medicine through innovative and scalable approaches.	Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.	Biomarker Identification Genomic Data Analysis	Light Search	United States	1998	5001 - 10000	$1.28B	Post-IPO Debt, $500.00M, September 6, 2024	Oct 14, 2024
Quanterix	Quanterix Corporation develops a highly sensitive platform for analyzing individual proteins and small molecules, enhancing clinical diagnostics and drug development. Their technology enables early disease detection and precise treatment methods across various therapeutic areas.	Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory, Homebrew - Custom Assay Development, and Uman NF-Light.	Biomarker Identification	Light Search	United States	2007	201 - 500	$850.30M	Grant, March 29, 2022	Oct 14, 2024